Literature DB >> 26025971

RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation.

Lynett Danks1, Noriko Komatsu2, Matteo M Guerrini1, Shinichiro Sawa1, Marietta Armaka3, George Kollias3, Tomoki Nakashima4, Hiroshi Takayanagi1.   

Abstract

OBJECTIVE: RANKL is mainly expressed by synovial fibroblasts and T cells within the joints of rheumatoid arthritis patients. The relative importance of RANKL expression by these cell types for the formation of bone erosions is unclear. We therefore aimed to quantify the contribution of RANKL by each cell type to osteoclast differentiation and bone destruction during inflammatory arthritis.
METHODS: RANKL was specifically deleted in T cells (Tnfsf11(flox/Δ) Lck-Cre), in collagen VI expressing cells including synovial fibroblasts (Tnfsf11(flox/Δ) Col6a1-Cre) and in collagen II expressing cells including articular chondrocytes (Tnfsf11(flox/Δ) Col2a1-Cre). Erosive disease was induced using the collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis (CIA) models. Osteoclasts and cartilage degradation were assessed by histology and bone erosions were assessed by micro-CT.
RESULTS: The inflammatory joint score during CAIA was equivalent in all mice regardless of cell-targeted deletion of RANKL. Significant increases in osteoclast numbers and bone erosions were observed in both the Tnfsf11(flox/Δ) and the Tnfsf11(flox/Δ) Lck-Cre groups during CAIA; however, the Tnfsf11(flox/Δ) Col6a1-Cre mice showed significant protection against osteoclast formation and bone erosions. Similar results on osteoclast formation and bone erosions were obtained in CIA mice. The deletion of RANKL on any cell type did not prevent articular cartilage loss in either model of arthritis used.
CONCLUSIONS: The expression of RANKL on synovial fibroblasts rather than T cells is predominantly responsible for the formation of osteoclasts and erosions during inflammatory arthritis. Synovial fibroblasts would be the best direct target in RANKL inhibition therapies. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Cytokines; Inflammation; Rheumatoid Arthritis; Synovitis; T Cells

Mesh:

Substances:

Year:  2015        PMID: 26025971     DOI: 10.1136/annrheumdis-2014-207137

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  78 in total

1.  Plasma cells promote osteoclastogenesis and periarticular bone loss in autoimmune arthritis.

Authors:  Noriko Komatsu; Stephanie Win; Minglu Yan; Nam Cong-Nhat Huynh; Shinichiro Sawa; Masayuki Tsukasaki; Asuka Terashima; Warunee Pluemsakunthai; George Kollias; Tomoki Nakashima; Hiroshi Takayanagi
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

2.  Nonsurgical periodontal therapy decreases the severity of rheumatoid arthritis and the plasmatic and salivary levels of RANKL and Survivin: a short-term clinical study.

Authors:  Marcela Faria Moura; Tarcília Aparecida Silva; Luís Otávio Miranda Cota; Sicilia Rezende Oliveira; Fernando Queiroz Cunha; Gilda Aparecida Ferreira; José Roberto Cortelli; Sheila Cavalca Cortelli; Fernando Oliveira Costa
Journal:  Clin Oral Investig       Date:  2021-05-05       Impact factor: 3.573

Review 3.  RANKL as the master regulator of osteoclast differentiation.

Authors:  Hiroshi Takayanagi
Journal:  J Bone Miner Metab       Date:  2021-01-01       Impact factor: 2.626

Review 4.  Arthritis models: usefulness and interpretation.

Authors:  Natacha Bessis; Patrice Decker; Eric Assier; Luca Semerano; Marie-Christophe Boissier
Journal:  Semin Immunopathol       Date:  2017-03-27       Impact factor: 9.623

Review 5.  RANKL as a therapeutic target of rheumatoid arthritis.

Authors:  Sakae Tanaka; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2020-10-18       Impact factor: 2.626

6.  Stepwise cell fate decision pathways during osteoclastogenesis at single-cell resolution.

Authors:  Masayuki Tsukasaki; Nam Cong-Nhat Huynh; Kazuo Okamoto; Ryunosuke Muro; Asuka Terashima; Yoshitaka Kurikawa; Noriko Komatsu; Warunee Pluemsakunthai; Takeshi Nitta; Takaya Abe; Hiroshi Kiyonari; Tadashi Okamura; Mashito Sakai; Toshiya Matsukawa; Michihiro Matsumoto; Yasuhiro Kobayashi; Josef M Penninger; Hiroshi Takayanagi
Journal:  Nat Metab       Date:  2020-12-07

7.  RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.

Authors:  Zhenqiang Yao; Wei Lei; Rong Duan; Yanyun Li; Lu Luo; Brendan F Boyce
Journal:  J Biol Chem       Date:  2017-04-24       Impact factor: 5.157

8.  Editorial: Inflammatory Osteoclasts: A Different Breed of Bone Eaters?

Authors:  Deborah Veis Novack
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

9.  RANK-Independent Osteoclast Formation and Bone Erosion in Inflammatory Arthritis.

Authors:  William O'Brien; Brian M Fissel; Yukiko Maeda; Jing Yan; Xianpeng Ge; Ellen M Gravallese; Antonios O Aliprantis; Julia F Charles
Journal:  Arthritis Rheumatol       Date:  2016-12       Impact factor: 10.995

10.  Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.

Authors:  Marilina Piemontese; Jinhu Xiong; Yuko Fujiwara; Jeff D Thostenson; Charles A O'Brien
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-07-26       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.